Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 7, 2025
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
GlobeNewswire
·
August 7, 2025
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a …
Genmab Announces Financial Results for the First Half of 2025
GlobeNewswire
·
August 7, 2025
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory …
Hemp Feed Coalition Secures AAFCO Official Publication for Hemp Seed Meal in Poultry Feed
GlobeNewswire
·
August 7, 2025
Omaha, NE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite this achievement, HFC and its members stress that the regulatory path to market for hemp feed remains riddled with bureaucratic obstacles. Because AAFCO’s approval alone does not grant automatic state- …
Shineco, Inc. to Effect 50:1 Reverse Stock Split
GlobeNewswire
·
August 7, 2025
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price BEIJING, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (Nasdaq:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical …
WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation
GlobeNewswire
·
August 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced that longserving WW board member Julie Rice, the entrepreneur and …
Allergy Diagnostics and Treatments Market to Reach $96.4 Billion by 2030
GlobeNewswire
·
August 7, 2025
Boston, Aug. 07, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Markets for Allergy Diagnostics and Treatments” is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual …
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
GlobeNewswire
·
August 7, 2025
Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR …
Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol
GlobeNewswire
·
August 7, 2025
Gildeuretinol acetate demonstrated less loss in ellipsoid zone (EZ) area compared to historical sibling controls. Early-stage Stargardt disease patients treated with gildeuretinol for two to seven years exhibited relatively stable disease over the course …
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
GlobeNewswire
·
August 7, 2025
CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP. CT-155 is an investigational prescription digital therapeutic being evaluated to target …
Vibrant Gastro Announces Federal Supply Schedule Contract Approval, Expanding Access to Veterans and Federal Health Patients
GlobeNewswire
·
August 7, 2025
Austin, TX, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro, inventor of the Vibrant® System, today announced that its FDA‑cleared, drug‑free treatment for chronic idiopathic constipation (CIC) is now available on the General Services Administration’s ( …
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
GlobeNewswire
·
August 7, 2025
EXTON, PA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), …
Recovery.com Acquires Recovery Brands Care Navigation Platform from American Addiction Centers in Eight-Figure Deal to Expand Access to Care
GlobeNewswire
·
August 7, 2025
MADISON, Wis., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Recovery.com and American Addiction Centers (AAC) today announced the sale and transition of several leading addiction treatment care navigation websites from AAC subsidiary Recovery Brands to Recovery.com. …
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
GlobeNewswire
·
August 7, 2025
SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ …
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
GlobeNewswire
·
August 7, 2025
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissue drug …
Alpha Pro Tech, Ltd. Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Net sales for the second quarter of 2025 were $16.7 million, up 2.4% compared to $16.3 million for the second quarter of 2024 Building Supply segment sales increased by $1.1 million, or 11.5%, to $11.1 million, compared to $9.9 million for the three months …
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
GlobeNewswire
·
August 7, 2025
CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the …
Kaléo Receives Inaugural Medical CBRN Defense Consortium Innovation Award for Prototype Development of its Rapid Opioid Countermeasure System (Naloxone HCl Injection, USP) Antidote
GlobeNewswire
·
August 7, 2025
Richmond, Virginia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injector innovation, today announced it received the Prototype Innovation award by the Medical CBRN Defense Consortium (MCDC) in …
Paragonix LIVERguard System Shown to Reduce Post-Transplant Complications in Transplant Recipients
GlobeNewswire
·
August 7, 2025
WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the presentation of impactful clinical data on the use of its advanced organ preservation …
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
GlobeNewswire
·
August 7, 2025
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well- …
Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
GlobeNewswire
·
August 7, 2025
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology …